ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Ocera Therapeutics, Inc." (OCRX) Report Updated: Jun 24, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Ocera Therapeutics, Inc." (OCRX)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: PAHC,ZTS,HSKA,SUPN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Ocera Therapeutics, Inc."© quotemedia

Company Profile

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.